If a researcher wanted to utilize CRISPR/Cas9 to target a gene of interest in their experimental system (i.e. Drosophila) which of the following would they customize for this purpose Group of answer choices Guiding region of sgRNA None of the above, CRISPR can only function in bacterial cells Cas9 enzyme Scaffold region of sgRNA

If a researcher wanted to utilize CRISPR/Cas9 to target a gene of interest in their experimental system (i.e. Drosophila) which of the following would they customize for this purpose Group of answer choices Guiding region of sgRNA None of the above, CRISPR can only function in bacterial cells Cas9 enzyme Scaffold region of sgRNA

Human Heredity: Principles and Issues (MindTap Course List)

11th Edition

ISBN:9781305251052

Author:Michael Cummings

Publisher:Michael Cummings

Chapter13: An Introduction To Genetic Technology

Section: Chapter Questions

Problem 19QP

See similar textbooks

Similar questions

Which of the following statements is not true about the guide RNA (see this interactive demonstration for help with this question: https://www.biointeractive.org/classroom-resources/crispr-cas9-mechanism-applications) Group of answer choices it contains a sequence of 20 nucleotides that matches a specific sequence in a cell’s DNA When the guide RNA is combined with Cas9, it will guide Cas9 to the target sequence its target sequence can be almost any sequence as long as it occurs near a PAM motif it is a nuclease, a type of enzyme that cleaves DNA
Researchers create a recombinant DNA molecule in which the coding sequence for GFP is inserted downstream of the enhancer/promoter for mouse rhodopsin. Then this DNA is used to to make a trangenic mouse. This is an example of a .... Group of answer choices Expression Vector Positional Clone Reporter Gene
CRISPR-Cas9 can be used by scientists to edit genes. This system was not created in a lab, however, but instead adapted from a system that already exists in nature. Describe the native biological function of CRISPR-Cas9.
Which of these statements is correct regarding the CRISPR/Cas9 system in eukaryotic cells? A.Single guide RNA (sgRNA) is used to target specific DNA sequences and activate Cas. B.Bacteriophages are used to inject viral genes into the cell to activated the Cas protein. C.CRISPR takes advantage of the cell’s DNA polymerase proof-reading activities for DNA replication errors D.The CRISPR-Cas system can only be used to alter genomes in prokaryotic cells. E. Cas cuts directly into palindromic restriction sites that it targets in the DNA.
Which of these statements is correct regarding the CRISPR/Cas9 system in eukaryotic cells? a.Single guide RNA (sgRNA) is used to target specific DNA sequences and activate Cas. b.Bacteriophages are used to inject viral genes into the cell to activated the Cas protein. c.CRISPR takes advantage of the cell’s DNA polymerase proof-reading activities for DNA replication errors d.The CRISPR-Cas system can only be used to alter genomes in prokaryotic cells. e.Cas cuts directly into palindromic restriction sites that it targets in the DNA.
Which of the following is NOT a true statement about CRISPR/Cas9?A. CRISPR/Cas9 is simpler to design than other gene editing technologies.B. CRISPR/Cas9 is derived from a bacterial adaptive immune defense system.C. CRISPR/Cas9 is more efficient than other gene editing technologies.D. CRISPR/Cas9 uses an RNA guide to edit a gene.E. Delivery of CRISPR/Cas9 is easier than delivery of other gene editing technologies.
You are employed in a gene therapy laboratory to test the effectiveness of a vector for correcting the DF508 –CFTR mutation. The vector uses CRISPR –CAS9 genome editing to correct the mutated gene in situ (CFTR-CRISPR). An Ussing chamber experiment was performed using nasal airway cells obtained from a patient with the DF508 CFTR mutation which were transformed with either a control vector consisting of an inert CRISPR-CAS-9 construct (CONTROL) or the active, gene correcting CRISPR CAS-9 construct (CFTR-CRISPR). The following transepithelial voltage values were obtained for the drug regimen shown under open circuit and current clamp (injected current of 10mA) conditions: CONTROL Baseline Amiloride Forskolin Inh172 Vte (mV) -78 -2 -4 -3 DVRt (mV) 8 16 7.5 13 R (W.cm-2) 800 1600 750 1300 I (mA.cm-2) 98 1 5 2 CFTR-CRISPR Vte (mV) -38 -6 -23 -9 DVRt (mV) 9 27 6 11 R (W.cm-2) 900 2700 600…
You are employed in a gene therapy laboratory to test the effectiveness of a vector for correcting the DF508 –CFTR mutation. The vector uses CRISPR –CAS9 genome editing to correct the mutated gene in situ (CFTR-CRISPR). An Ussing chamber experiment was performed using nasal airway cells obtained from a patient with the DF508 CFTR mutation which were transformed with either a control vector consisting of an inert CRISPR-CAS-9 construct (CONTROL) or the active, gene correcting CRISPR CAS-9 construct (CFTR-CRISPR). The following transepithelial voltage values were obtained for the drug regimen shown under open circuit and current clamp (injected current of 10mA) conditions: CONTROL Baseline Amiloride Forskolin Inh172 Vte (mV) -78 -2 -4 -3 DVRt (mV) 8 16 7.5 13 R (W.cm-2) 800 1600 750 1300 I (mA.cm-2) 98 1 5 2 CFTR-CRISPR Vte (mV) -38 -6 -23 -9 DVRt (mV) 9 27 6 11 R (W.cm-2) 900 2700 600…
You are employed in a gene therapy laboratory to test the effectiveness of a vector for correcting the DF508 –CFTR mutation. The vector uses CRISPR –CAS9 genome editing to correct the mutated gene in situ (CFTR-CRISPR). An Ussing chamber experiment was performed using nasal airway cells obtained from a patient with the DF508 CFTR mutation which were transformed with either a control vector consisting of an inert CRISPR-CAS-9 construct (CONTROL) or the active, gene correcting CRISPR CAS-9 construct (CFTR-CRISPR). The following transepithelial voltage values were obtained for the drug regimen shown under open circuit and current clamp (injected current of 10mA) conditions: CONTROL Baseline Amiloride Forskolin Inh172 Vte (mV) -78 -2 -4 -3 DVRt (mV) 8 16 7.5 13 R (W.cm-2) 800 1600 750 1300 I (mA.cm-2) 98 1 5 2 CFTR-CRISPR Vte (mV) -38 -6 -23 -9 DVRt (mV) 9 27 6 11 R (W.cm-2) 900 2700 600…
You are employed in a gene therapy laboratory to test the effectiveness of a vector for correcting the DF508 –CFTR mutation. The vector uses CRISPR –CAS9 genome editing to correct the mutated gene in situ (CFTR-CRISPR). An Ussing chamber experiment was performed using nasal airway cells obtained from a patient with the DF508 CFTR mutation which were transformed with either a control vector consisting of an inert CRISPR-CAS-9 construct (CONTROL) or the active, gene correcting CRISPR CAS-9 construct (CFTR-CRISPR). The following transepithelial voltage values were obtained for the drug regimen shown under open circuit and current clamp (injected current of 10mA) conditions: CONTROL Baseline Amiloride Forskolin Inh172 Vte (mV) -78 -2 -4 -3 DVRt (mV) 8 16 7.5 13 R (W.cm-2) 800 1600 750 1300 I (mA.cm-2) 98 1 5 2 CFTR-CRISPR Vte (mV) -38 -6 -23 -9 DVRt (mV) 9 27 6 11 R (W.cm-2) 900 2700 600…
You are employed in a gene therapy laboratory to test the effectiveness of a vector for correcting the DF508 –CFTR mutation. The vector uses CRISPR –CAS9 genome editing to correct the mutated gene in situ (CFTR-CRISPR). An Ussing chamber experiment was performed using nasal airway cells obtained from a patient with the DF508 CFTR mutation which were transformed with either a control vector consisting of an inert CRISPR-CAS-9 construct (CONTROL) or the active, gene correcting CRISPR CAS-9 construct (CFTR-CRISPR). The following transepithelial voltage values were obtained for the drug regimen shown under open circuit and current clamp (injected current of 10mA) conditions: CONTROL Baseline Amiloride Forskolin Inh172 Vte (mV) -78 -2 -4 -3 DVRt (mV) 8 16 7.5 13 R (W.cm-2) 800 1600 750 1300 I (mA.cm-2) 98 1 5 2 CFTR-CRISPR Vte (mV) -38 -6 -23 -9 DVRt (mV) 9 27 6 11 R (W.cm-2) 900 2700 600…
You are employed in a gene therapy laboratory to test the effectiveness of a vector for correcting the DF508 –CFTR mutation. The vector uses CRISPR –CAS9 genome editing to correct the mutated gene in situ (CFTR-CRISPR). An Ussing chamber experiment was performed using nasal airway cells obtained from a patient with the DF508 CFTR mutation which were transformed with either a control vector consisting of an inert CRISPR-CAS-9 construct (CONTROL) or the active, gene correcting CRISPR CAS-9 construct (CFTR-CRISPR). The following transepithelial voltage values were obtained for the drug regimen shown under open circuit and current clamp (injected current of 10mA) conditions: CONTROL Baseline Amiloride Forskolin Inh172 Vte (mV) -78 -2 -4 -3 DVRt (mV) 8 16 7.5 13 R (W.cm-2) 800 1600 750 1300 I (mA.cm-2) 98 1 5 2 CFTR-CRISPR Vte (mV) -38 -6 -23 -9 DVRt (mV) 9 27 6 11 R (W.cm-2) 900 2700 600…